Sharon Mindlin Steinberg, M.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpesvirus 3, Human | 47 | 2014 | 204 | 2.200 |
Why?
|
| Chickenpox Vaccine | 35 | 2014 | 79 | 1.970 |
Why?
|
| Chickenpox | 35 | 2011 | 131 | 1.530 |
Why?
|
| Herpes Zoster | 22 | 2010 | 264 | 0.720 |
Why?
|
| Education, Nursing, Graduate | 3 | 2006 | 15 | 0.680 |
Why?
|
| Managed Care Programs | 3 | 2006 | 950 | 0.440 |
Why?
|
| Antibodies, Viral | 25 | 2014 | 3176 | 0.430 |
Why?
|
| Nurse Practitioners | 2 | 2006 | 270 | 0.390 |
Why?
|
| Nurse Clinicians | 2 | 2002 | 31 | 0.380 |
Why?
|
| Viral Vaccines | 15 | 2013 | 636 | 0.370 |
Why?
|
| Preceptorship | 1 | 2006 | 61 | 0.280 |
Why?
|
| Exanthema | 8 | 2013 | 501 | 0.230 |
Why?
|
| Vaccination | 14 | 2010 | 3278 | 0.220 |
Why?
|
| DNA, Viral | 13 | 2010 | 2226 | 0.190 |
Why?
|
| Curriculum | 3 | 2006 | 3604 | 0.180 |
Why?
|
| Vaccines, Attenuated | 16 | 2010 | 342 | 0.180 |
Why?
|
| Fluorescent Antibody Technique | 11 | 2011 | 2505 | 0.150 |
Why?
|
| Health Personnel | 4 | 2011 | 3216 | 0.130 |
Why?
|
| Educational Measurement | 1 | 2002 | 1209 | 0.120 |
Why?
|
| Viral Envelope Proteins | 3 | 2014 | 635 | 0.120 |
Why?
|
| Immunization Schedule | 3 | 2011 | 221 | 0.120 |
Why?
|
| Leukemia | 6 | 1991 | 1508 | 0.120 |
Why?
|
| Latex Fixation Tests | 2 | 2001 | 32 | 0.120 |
Why?
|
| Leukemia, Lymphoid | 4 | 1988 | 313 | 0.110 |
Why?
|
| Herpesviridae Infections | 1 | 2014 | 277 | 0.110 |
Why?
|
| Luciferases | 1 | 2014 | 733 | 0.100 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 905 | 0.100 |
Why?
|
| Fluoroimmunoassay | 1 | 2010 | 33 | 0.100 |
Why?
|
| Immunity | 2 | 2011 | 1012 | 0.100 |
Why?
|
| Encephalitis, Varicella Zoster | 1 | 2010 | 9 | 0.090 |
Why?
|
| Genome, Viral | 1 | 2013 | 667 | 0.090 |
Why?
|
| Immunization, Secondary | 2 | 2009 | 340 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 8 | 2011 | 6172 | 0.080 |
Why?
|
| Immunity, Cellular | 4 | 1990 | 1607 | 0.070 |
Why?
|
| Selection, Genetic | 2 | 2013 | 914 | 0.070 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2008 | 469 | 0.070 |
Why?
|
| Immunocompromised Host | 3 | 2014 | 847 | 0.070 |
Why?
|
| Antigens, Viral | 6 | 2010 | 1035 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 1620 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2008 | 430 | 0.070 |
Why?
|
| Interinstitutional Relations | 1 | 2006 | 240 | 0.070 |
Why?
|
| Nurse's Role | 1 | 2006 | 209 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2006 | 778 | 0.060 |
Why?
|
| Clinical Competence | 1 | 1999 | 4687 | 0.060 |
Why?
|
| Nursing Education Research | 1 | 2002 | 12 | 0.050 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 2005 | 768 | 0.050 |
Why?
|
| Child | 27 | 2011 | 77679 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 1999 | 5319 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2011 | 5974 | 0.050 |
Why?
|
| Occupational Exposure | 1 | 2011 | 1796 | 0.050 |
Why?
|
| Skin | 1 | 2013 | 4363 | 0.040 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 14726 | 0.040 |
Why?
|
| Job Description | 1 | 1999 | 58 | 0.040 |
Why?
|
| Humans | 56 | 2014 | 744220 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2013 | 15525 | 0.040 |
Why?
|
| Psychology | 1 | 1979 | 356 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2001 | 3871 | 0.040 |
Why?
|
| Inservice Training | 1 | 1979 | 392 | 0.040 |
Why?
|
| Antigens, Surface | 2 | 2011 | 1663 | 0.030 |
Why?
|
| Genetic Variation | 2 | 2007 | 6546 | 0.030 |
Why?
|
| Health Maintenance Organizations | 2 | 1991 | 642 | 0.030 |
Why?
|
| Organizational Innovation | 1 | 1999 | 559 | 0.030 |
Why?
|
| Infant | 13 | 2008 | 35129 | 0.030 |
Why?
|
| Restriction Mapping | 3 | 2010 | 878 | 0.030 |
Why?
|
| Child, Preschool | 14 | 2008 | 40992 | 0.030 |
Why?
|
| T-Lymphocytes | 3 | 2009 | 10182 | 0.030 |
Why?
|
| Boston | 2 | 2006 | 9311 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2003 | 2133 | 0.030 |
Why?
|
| Leukocytes | 2 | 1979 | 2040 | 0.030 |
Why?
|
| Psychiatry | 3 | 1991 | 1695 | 0.030 |
Why?
|
| Immune Tolerance | 3 | 1986 | 2258 | 0.030 |
Why?
|
| Psychiatric Nursing | 1 | 1991 | 17 | 0.030 |
Why?
|
| Adult | 21 | 2014 | 214035 | 0.030 |
Why?
|
| Training Support | 1 | 1991 | 113 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1991 | 1676 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 3 | 2007 | 4803 | 0.020 |
Why?
|
| Immunoglobulin G | 3 | 2011 | 4559 | 0.020 |
Why?
|
| Antibody Affinity | 1 | 2010 | 254 | 0.020 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2011 | 102 | 0.020 |
Why?
|
| Genotype | 3 | 2013 | 12956 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2014 | 1849 | 0.020 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 2 | 2005 | 170 | 0.020 |
Why?
|
| Male | 20 | 2014 | 350027 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2013 | 18116 | 0.020 |
Why?
|
| Tennessee | 1 | 2008 | 117 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2014 | 945 | 0.020 |
Why?
|
| Female | 22 | 2011 | 380197 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2014 | 1380 | 0.020 |
Why?
|
| Time Factors | 6 | 2008 | 40063 | 0.020 |
Why?
|
| Case-Control Studies | 4 | 2011 | 21752 | 0.020 |
Why?
|
| Phylogeny | 1 | 2013 | 2803 | 0.020 |
Why?
|
| Intradermal Tests | 1 | 1985 | 44 | 0.020 |
Why?
|
| Viral Proteins | 2 | 1990 | 1900 | 0.020 |
Why?
|
| New York | 1 | 2008 | 886 | 0.020 |
Why?
|
| Adolescent | 11 | 2008 | 85759 | 0.020 |
Why?
|
| Middle Aged | 11 | 2014 | 213367 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 1991 | 1519 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1985 | 485 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 1939 | 0.020 |
Why?
|
| Immunization | 1 | 1989 | 1256 | 0.020 |
Why?
|
| Immunoassay | 1 | 1988 | 752 | 0.020 |
Why?
|
| Immunity, Active | 1 | 2004 | 60 | 0.020 |
Why?
|
| California | 1 | 2008 | 1402 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2007 | 547 | 0.010 |
Why?
|
| Skin Tests | 1 | 1985 | 612 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2006 | 810 | 0.010 |
Why?
|
| ROC Curve | 1 | 2011 | 3527 | 0.010 |
Why?
|
| Genes, Viral | 1 | 2004 | 718 | 0.010 |
Why?
|
| HIV Infections | 1 | 2009 | 16718 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 1991 | 1076 | 0.010 |
Why?
|
| Respiratory System | 1 | 2006 | 557 | 0.010 |
Why?
|
| Alleles | 1 | 2013 | 6938 | 0.010 |
Why?
|
| Psychotherapy | 1 | 1991 | 1645 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2005 | 453 | 0.010 |
Why?
|
| Counterimmunoelectrophoresis | 1 | 1981 | 15 | 0.010 |
Why?
|
| Immunoelectrophoresis | 1 | 1981 | 110 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 3598 | 0.010 |
Why?
|
| Erythema Multiforme | 1 | 2000 | 31 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1990 | 6461 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2004 | 2256 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2006 | 3588 | 0.010 |
Why?
|
| Incidence | 2 | 2008 | 20945 | 0.010 |
Why?
|
| Point Mutation | 1 | 2005 | 1624 | 0.010 |
Why?
|
| Virus Activation | 1 | 2000 | 319 | 0.010 |
Why?
|
| Ataxia | 1 | 2000 | 304 | 0.010 |
Why?
|
| Immunization Programs | 1 | 2001 | 260 | 0.010 |
Why?
|
| Immune System | 1 | 2003 | 805 | 0.010 |
Why?
|
| Teaching | 1 | 1985 | 1174 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 1623 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1982 | 1538 | 0.010 |
Why?
|
| Aged | 6 | 2010 | 163253 | 0.010 |
Why?
|
| Safety | 1 | 2000 | 1185 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 2 | 1987 | 570 | 0.010 |
Why?
|
| Age Factors | 2 | 2004 | 18367 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2005 | 2924 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 3509 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 2002 | 15538 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 4328 | 0.010 |
Why?
|
| Anaphylaxis | 1 | 2000 | 746 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 13990 | 0.010 |
Why?
|
| Interprofessional Relations | 1 | 1979 | 1009 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2000 | 1175 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 13817 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 7908 | 0.010 |
Why?
|
| Social Work, Psychiatric | 1 | 1991 | 24 | 0.010 |
Why?
|
| Cell Line | 2 | 1992 | 15999 | 0.010 |
Why?
|
| Skin Diseases, Infectious | 1 | 1991 | 74 | 0.010 |
Why?
|
| Psychology, Clinical | 1 | 1991 | 42 | 0.010 |
Why?
|
| United States | 1 | 1999 | 69867 | 0.010 |
Why?
|
| Glycoproteins | 2 | 1990 | 2263 | 0.010 |
Why?
|
| Massachusetts | 2 | 1985 | 8663 | 0.010 |
Why?
|
| DNA Probes | 1 | 1992 | 560 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 708 | 0.010 |
Why?
|
| Internship and Residency | 2 | 1991 | 5787 | 0.010 |
Why?
|
| Monocytes | 1 | 1979 | 2594 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 1981 | 2958 | 0.010 |
Why?
|
| Follow-Up Studies | 3 | 2002 | 39045 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1979 | 2529 | 0.000 |
Why?
|
| Serologic Tests | 1 | 1990 | 374 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2008 | 23337 | 0.000 |
Why?
|
| Prospective Studies | 2 | 2001 | 53280 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1992 | 4321 | 0.000 |
Why?
|
| Physician-Patient Relations | 1 | 1979 | 3227 | 0.000 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1988 | 1801 | 0.000 |
Why?
|
| Species Specificity | 1 | 1990 | 2480 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2008 | 40559 | 0.000 |
Why?
|
| Young Adult | 1 | 2010 | 56436 | 0.000 |
Why?
|
| Bone Marrow Transplantation | 1 | 1991 | 2763 | 0.000 |
Why?
|
| Complement Fixation Tests | 1 | 1982 | 78 | 0.000 |
Why?
|
| Base Sequence | 1 | 1992 | 12801 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1982 | 795 | 0.000 |
Why?
|
| Herpes Simplex | 1 | 1982 | 470 | 0.000 |
Why?
|
| Family | 1 | 1990 | 3148 | 0.000 |
Why?
|
| Disease Susceptibility | 1 | 1985 | 1782 | 0.000 |
Why?
|
| Fetal Blood | 1 | 1982 | 1317 | 0.000 |
Why?
|
| Adaptation, Psychological | 1 | 1985 | 2576 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1985 | 5523 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2001 | 63119 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1984 | 3748 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 1988 | 15070 | 0.000 |
Why?
|
| Attitude of Health Personnel | 1 | 1985 | 3842 | 0.000 |
Why?
|
| Risk Factors | 1 | 1991 | 72280 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1981 | 25618 | 0.000 |
Why?
|
| Pregnancy | 1 | 1982 | 29142 | 0.000 |
Why?
|